Improved human endometrial stem cells differentiation into functional hepatocyte‐like cells on a glycosaminoglycan/collagen‐grafted polyethersulfone nanofibrous scaffold. Issue 8 (30th September 2016)

• Record Type: Journal Article
• Authors: Khademi, Farzaneh; Ai, Jafar; Soleimani, Masoud; Verdi, Javad; Mohammad Tavangar, Seyed; Sadroddiny, Esmaeil; Massumi, Mohammad; Mahmoud Hashemi, Seyed
• Is Part Of: Journal of biomedical materials research. Volume 105:Issue 8(2017)
• Page Start: 2516
• Page End: 2529
• Publication Date: 2016-09-30
• Subjects: human endometrial stem cells -- polyethersulfone nanofibrous scaffold -- heparan sulfate -- collagen -- liver tissue engineering; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1002/jbm.b.33758
• Languages: English
• ISSNs: 1552-4973

Abstract

Abstract: Liver tissue engineering (TE) is rapidly emerging as an effective technique which combines engineering and biological processes to compensate for the shortage of damaged or destroyed liver tissues. We examined the viability, differentiation, and integration of hepatocyte‐like cells on an electrospun polyethersulfone (PES) scaffold, derived from human endometrial stem cells (hEnSCs). Natural polymers were separately grafted on plasma‐treated PES nanofibers, that is, collagen, heparan sulfate (HS) and collagen–HS. Galactosilated PES (PES‐Gal) nanofibrous were created. The engineering and cell growth parameters were considered and compared with each sample. The cellular studies revealed increased cell survival, attachment, and normal morphology on the bioactive natural polymer‐grafted scaffolds after 30 days of hepatic differentiation. The chemical and molecular assays displayed hepatocyte differentiation. These cells were also functional, showing glycogen storage, α‐fetoprotein, and albumin secretion. The HS nanoparticle‐grafted PES nanofibers demonstrated a high rate of cell proliferation, differentiation, and integration. Based on the observations mentioned above, engineered tissue is a good option in the future, for the commercial production of three‐dimensional liver tissues for clinical purposes. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 105B: 2516–2529, 2017.